BINDER BRANT - 14 Jul 2023 Form 4 Insider Report for Eterna Therapeutics Inc. (ERNA)

Role: Director
Signature: /s/ Brant Binder
Issuer symbol: ERNA
Transactions as of: 14 Jul 2023
Net transactions value: +$130,490
Form type: 4
Filing time: 18 Jul 2023, 16:15:35 UTC
Previous filing: 11 Jul 2023
Next filing: 10 Aug 2023
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ERNA	6.0% Senior Convertible Promissory Notes due 2028	Purchase	$120,000				$120,000	13 Jul 2023	Common Stock	41,958	$2.86	Direct	F1
transaction	ERNA	Warrants (right to buy)	Purchase	$10,490	+83,916		$0.1250^*	83,916	13 Jul 2023	Common Stock	83,916	$2.61	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reporting person entered into a Securities Purchase Agreement with the Issuer on July 13, 2023, pursuant to which, on July 14, 2023, the reporting person acquired $120,000 principal amount of the Issuer's 6.0% Senior Convertible Promissory Notes due July 2028 (the "Notes") and (ii) 83,916 warrants, each exercisable to purchase one share of the Company's common stock, par value $0.005 per share ("Common Stock"), at an exercise price of $2.61 per share (the "Warrants"), representing 200% of the number of shares of Common Stock issuable upon conversion of the Notes immediately after the issuance thereof. The conversion price for each Note included $0.25 ($0.125 for each Warrant share) in accordance with Nasdaq rules.

Content

The reporting person entered into a Securities Purchase Agreement with the Issuer on July 13, 2023, pursuant to which, on July 14, 2023, the reporting person acquired $120,000 principal amount of the Issuer's 6.0% Senior Convertible Promissory Notes due July 2028 (the "Notes") and (ii) 83,916 warrants, each exercisable to purchase one share of the Company's common stock, par value $0.005 per share ("Common Stock"), at an exercise price of $2.61 per share (the "Warrants"), representing 200% of the number of shares of Common Stock issuable upon conversion of the Notes immediately after the issuance thereof. The conversion price for each Note included $0.25 ($0.125 for each Warrant share) in accordance with Nasdaq rules.